In a new study led by Johns Hopkins Medicine, the experimental drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis), which is often incurable. Researchers say this study moves them closer to clinical trials for RK-33.
